2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC-Related Custom Services

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-155744
    Acetylene-PEG3-MMAF-OMe
    Acetylene-PEG3-MMAF-OMe (LCB14-0536) is a protein-active agent conjugate. Acetylene-PEG3-MMAF-OMe can be recognized by isoprenoid transferase. Acetylene-PEG3-MMAF-OMe is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Acetylene-PEG3-MMAF-OMe
  • HY-164706
    m-PEG6-Lys-Mal-Toxophore-quinoline
    m-PEG6-Lys-Mal-Toxophore-quinoline is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-164760).
    m-PEG6-Lys-Mal-Toxophore-quinoline
  • HY-145365
    DGN549-L
    DGN549-L is a DNA alkylator and can be utilized for antibody conjugation at lysine residues. DGN549-L can be used in the synthesis of antibody-drug conjugates (ADCs).
    DGN549-L
  • HY-137774
    Clezutoclax
    Clezutoclax is a agent-linker conjugate for ADC . Clezutoclax can be used in the synthesis of antibody-drug conjugates (ADCs).
    Clezutoclax
  • HY-128961
    MC-Alkyl-Hydrazine Modified MMAF
    MC-Alkyl-Hydrazine Modified MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the Modified MMAF (a tubulin inhibitor), linked via the noncleavable MC-Alkyl-Hydrazine.
    MC-Alkyl-Hydrazine Modified MMAF
  • HY-158349
    Mal-Val-Ala-PAB-4-Abu(Me)-Dazostinag
    Mal-Val-Ala-PAB-4-Abu(Me)-Dazostinag is a drug-linker conjugate for ADC.
    Mal-Val-Ala-PAB-4-Abu(Me)-Dazostinag
  • HY-13631ES
    Deruxtecan-d4
    Deruxtecan-d4 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d<sub>4</sub>
  • HY-153395
    PH-HG-005-5
    		99.51%
    PH-HG-005-5 (compound 16c) is a derivative of SN-38 (HY-13704) and can be used as Drug-Linker Conjugates for ADC. PH-HG-005-5 can conjugate to targeting peptides for ADCs synthesis.
    PH-HG-005-5
  • HY-153069A
    GGFG-PAB-Exatecan TFA
    GGFG-PAB-Exatecan TFA consists of an ADC toxin Exatecan (HY-13631) and a linker GGFG-PAB, and can be used as a drug-linker conjugate for the synthesis of ADC molecules.
    GGFG-PAB-Exatecan TFA
  • HY-160756A
    Val-Cit-Exatecan TFA
    Val-Cit-Exatecan TFA is an agent-linker conjugate for ADC. Val-Cit-Exatecan TFA is composed of a DNA topoisomerase I Exatecan (HY-13631) and a cathepsin cleavable ADC linker.
    Val-Cit-Exatecan TFA
  • HY-145943
    MP-PEG8-Val-Lys-Ala-7-MAD-MDCPT
    MP-PEG8-Val-Lys-Ala-7-MAD-MDCPT is a agent-linker conjugate for antibody-drug conjugate (ADC). MP-PEG8-Val-Lys-Ala-7-MAD-MDCPT has the potential for cancer and autoimmune disease research.
    MP-PEG8-Val-Lys-Ala-7-MAD-MDCPT
  • HY-163673
    Glucocorticoid receptor modulator 4
    Glucocorticoid receptor modulator 4 (Compound DL5) is a conjugate of a linker and a glucocorticoid receptor modulator. Glucocorticoid receptor modulator 4 exhibits GRE Reporter activity in mTNF expressing K562 cell with an EC50 of 40 μM. Glucocorticoid receptor modulator 4 binds with an anti-tumor necrosis factor (TNF) antibody, and exhibits anti-inflammtory activity against arthritis in mouse models.
    Glucocorticoid receptor modulator 4
  • HY-172554
    XMT-2056 drug-linker
    XMT-2056 drug-linker is a drug-linker conjugate linker for a HER2-Directed STING Agonist antibody-Drug Conjugate (XMT-2056, Calotatug ginistinag). Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate targeting HER2, with an effective payload connected via a linker (LP, HY-148067) to a STING agonist (STING agonist-20, HY-148068), and has potential immune activation and anticancer activity.
    XMT-2056 drug-linker
  • HY-173625
    P5(PEG12)-VC-PAB-Exatecan
    P5(PEG12)-VC-PAB-Exatecan (LP3) is a drug-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor Exatecan (HY-13631) and a linker P5(PEG24)-VC-PAB to make antibody agent conjugate (ADC). P5(PEG12)-VC-PAB-Exatecan can be used for the research of tumor.
    P5(PEG12)-VC-PAB-Exatecan
  • HY-126493A
    (R)-DM4-SPDP
    (R)-DM4-SPDP is a conjugate made up of the linker SPDP and the toxic molecule DM4, and it can be used to prepare antibody-drug conjugates.
    (R)-DM4-SPDP
  • HY-13631ES4
    Deruxtecan-d5
    Deruxtecan-d5 is deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d<sub>5</sub>
  • HY-P99881
    Rolinsatamab talirine
    Rolinsatamab talirine (ABBV 176) is an antibody-drug conjugate (ADC) targeting prolactin receptor (PRLR). Rolinsatamab talirine consists of rolinsatamab (HY-P99238), an enzymatically cleavable peptide linker, and SGD-1882 (HY-101127).
    Rolinsatamab talirine
  • HY-171508
    Mal-PNU-159682
    Mal-PNU-159682 is a Drug-Linker Conjugates for ADC, composes of ADC linker (maleimide) and ADC cytotoxin PNU-159682 (HY-16700), and has anti-tumor activity.
    Mal-PNU-159682
  • HY-13631ES2
    Deruxtecan-d4-1
    Deruxtecan-d4-1 is the deuterium labeled Adenosine Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d<sub>4</sub>-1
  • HY-139325A
    NHS-Modified MMAF TFA
    NHS-Modified MMAF (intermediat 210) TFA is an intermediate which can be used for producing the anti-mesothelin binder-agent conjugates (ADCs).
    NHS-Modified MMAF TFA
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.